世界の血液悪性腫瘍市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hematologic Malignancies Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2759 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、血液悪性腫瘍のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（白血病、リンパ腫、多発性骨髄腫、その他）、用途別市場規模（化学療法、放射線療法、免疫療法、幹細胞移植、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・血液悪性腫瘍の市場動向 ・企業の競争状況、市場シェア ・血液悪性腫瘍の種類別市場規模（白血病、リンパ腫、多発性骨髄腫、その他） ・血液悪性腫瘍の用途別市場規模（化学療法、放射線療法、免疫療法、幹細胞移植、その他） ・血液悪性腫瘍の北米市場規模2016-2027（アメリカ、カナダ） ・血液悪性腫瘍のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・血液悪性腫瘍のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・血液悪性腫瘍の中南米市場規模2016-2027（メキシコ、ブラジル） ・血液悪性腫瘍の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer, Inc.、F. Hoffmann-LA Roche ltd、Sanofi-Aventis、Bristol-Myers Squibb Company、AbbVie, Inc.、Novartis AG、GlaxoSmithKline PLC、Celgene Corporation、Johnson & Johnson Services, Inc.、Takeda Pharmaceutical Company limited） ・結論

Market Analysis and Insights: Global Hematologic Malignancies Market
The global Hematologic Malignancies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematologic Malignancies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematologic Malignancies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematologic Malignancies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematologic Malignancies market.

Global Hematologic Malignancies Scope and Market Size
Hematologic Malignancies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hematologic Malignancies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Leukemia
Lymphoma
Multiple Myeloma
Others

Segment by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Multiple Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.3.4 Immunotherapy
1.3.5 Stem Cell Transplantation
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hematologic Malignancies Market Perspective (2016-2027)
2.2 Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hematologic Malignancies Historic Market Share by Regions (2016-2021)
2.2.3 Hematologic Malignancies Forecasted Market Size by Regions (2022-2027)
2.3 Hematologic Malignancies Industry Dynamic
2.3.1 Hematologic Malignancies Market Trends
2.3.2 Hematologic Malignancies Market Drivers
2.3.3 Hematologic Malignancies Market Challenges
2.3.4 Hematologic Malignancies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Players by Revenue
3.1.1 Global Top Hematologic Malignancies Players by Revenue (2016-2021)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2016-2021)
3.2 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Revenue
3.4 Global Hematologic Malignancies Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2020
3.5 Hematologic Malignancies Key Players Head office and Area Served
3.6 Key Players Hematologic Malignancies Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hematologic Malignancies Breakdown Data by Type
4.1 Global Hematologic Malignancies Historic Market Size by Type (2016-2021)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2022-2027)

5 Hematologic Malignancies Breakdown Data by Application
5.1 Global Hematologic Malignancies Historic Market Size by Application (2016-2021)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hematologic Malignancies Market Size (2016-2027)
6.2 North America Hematologic Malignancies Market Size by Type
6.2.1 North America Hematologic Malignancies Market Size by Type (2016-2021)
6.2.2 North America Hematologic Malignancies Market Size by Type (2022-2027)
6.2.3 North America Hematologic Malignancies Market Size by Type (2016-2027)
6.3 North America Hematologic Malignancies Market Size by Application
6.3.1 North America Hematologic Malignancies Market Size by Application (2016-2021)
6.3.2 North America Hematologic Malignancies Market Size by Application (2022-2027)
6.3.3 North America Hematologic Malignancies Market Size by Application (2016-2027)
6.4 North America Hematologic Malignancies Market Size by Country
6.4.1 North America Hematologic Malignancies Market Size by Country (2016-2021)
6.4.2 North America Hematologic Malignancies Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Hematologic Malignancies Market Size (2016-2027)
7.2 Europe Hematologic Malignancies Market Size by Type
7.2.1 Europe Hematologic Malignancies Market Size by Type (2016-2021)
7.2.2 Europe Hematologic Malignancies Market Size by Type (2022-2027)
7.2.3 Europe Hematologic Malignancies Market Size by Type (2016-2027)
7.3 Europe Hematologic Malignancies Market Size by Application
7.3.1 Europe Hematologic Malignancies Market Size by Application (2016-2021)
7.3.2 Europe Hematologic Malignancies Market Size by Application (2022-2027)
7.3.3 Europe Hematologic Malignancies Market Size by Application (2016-2027)
7.4 Europe Hematologic Malignancies Market Size by Country
7.4.1 Europe Hematologic Malignancies Market Size by Country (2016-2021)
7.4.2 Europe Hematologic Malignancies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Market Size (2016-2027)
8.2 Asia-Pacific Hematologic Malignancies Market Size by Type
8.2.1 Asia-Pacific Hematologic Malignancies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hematologic Malignancies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hematologic Malignancies Market Size by Type (2016-2027)
8.3 Asia-Pacific Hematologic Malignancies Market Size by Application
8.3.1 Asia-Pacific Hematologic Malignancies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hematologic Malignancies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hematologic Malignancies Market Size by Application (2016-2027)
8.4 Asia-Pacific Hematologic Malignancies Market Size by Region
8.4.1 Asia-Pacific Hematologic Malignancies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hematologic Malignancies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hematologic Malignancies Market Size (2016-2027)
9.2 Latin America Hematologic Malignancies Market Size by Type
9.2.1 Latin America Hematologic Malignancies Market Size by Type (2016-2021)
9.2.2 Latin America Hematologic Malignancies Market Size by Type (2022-2027)
9.2.3 Latin America Hematologic Malignancies Market Size by Type (2016-2027)
9.3 Latin America Hematologic Malignancies Market Size by Application
9.3.1 Latin America Hematologic Malignancies Market Size by Application (2016-2021)
9.3.2 Latin America Hematologic Malignancies Market Size by Application (2022-2027)
9.3.3 Latin America Hematologic Malignancies Market Size by Application (2016-2027)
9.4 Latin America Hematologic Malignancies Market Size by Country
9.4.1 Latin America Hematologic Malignancies Market Size by Country (2016-2021)
9.4.2 Latin America Hematologic Malignancies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Market Size (2016-2027)
10.2 Middle East & Africa Hematologic Malignancies Market Size by Type
10.2.1 Middle East & Africa Hematologic Malignancies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hematologic Malignancies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hematologic Malignancies Market Size by Type (2016-2027)
10.3 Middle East & Africa Hematologic Malignancies Market Size by Application
10.3.1 Middle East & Africa Hematologic Malignancies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hematologic Malignancies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hematologic Malignancies Market Size by Application (2016-2027)
10.4 Middle East & Africa Hematologic Malignancies Market Size by Country
10.4.1 Middle East & Africa Hematologic Malignancies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hematologic Malignancies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
11.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2016-2021)
11.1.5 Pfizer, Inc. Recent Development
11.2 F. Hoffmann-LA Roche ltd
11.2.1 F. Hoffmann-LA Roche ltd Company Details
11.2.2 F. Hoffmann-LA Roche ltd Business Overview
11.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
11.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2016-2021)
11.2.5 F. Hoffmann-LA Roche ltd Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Company Details
11.3.2 Sanofi-Aventis Business Overview
11.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
11.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2016-2021)
11.3.5 Sanofi-Aventis Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2016-2021)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 AbbVie, Inc.
11.5.1 AbbVie, Inc. Company Details
11.5.2 AbbVie, Inc. Business Overview
11.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
11.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2016-2021)
11.5.5 AbbVie, Inc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hematologic Malignancies Introduction
11.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2016-2021)
11.6.5 Novartis AG Recent Development
11.7 GlaxoSmithKline PLC
11.7.1 GlaxoSmithKline PLC Company Details
11.7.2 GlaxoSmithKline PLC Business Overview
11.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
11.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2016-2021)
11.7.5 GlaxoSmithKline PLC Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Hematologic Malignancies Introduction
11.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2016-2021)
11.8.5 Celgene Corporation Recent Development
11.9 Johnson & Johnson Services, Inc.
11.9.1 Johnson & Johnson Services, Inc. Company Details
11.9.2 Johnson & Johnson Services, Inc. Business Overview
11.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
11.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2016-2021)
11.9.5 Johnson & Johnson Services, Inc. Recent Development
11.10 Takeda Pharmaceutical Company limited
11.10.1 Takeda Pharmaceutical Company limited Company Details
11.10.2 Takeda Pharmaceutical Company limited Business Overview
11.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Introduction
11.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2016-2021)
11.10.5 Takeda Pharmaceutical Company limited Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hematologic Malignancies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Leukemia
Table 3. Key Players of Lymphoma
Table 4. Key Players of Multiple Myeloma
Table 5. Key Players of Others
Table 6. Global Hematologic Malignancies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Hematologic Malignancies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hematologic Malignancies Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Hematologic Malignancies Market Share by Regions (2016-2021)
Table 10. Global Hematologic Malignancies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Hematologic Malignancies Market Share by Regions (2022-2027)
Table 12. Hematologic Malignancies Market Trends
Table 13. Hematologic Malignancies Market Drivers
Table 14. Hematologic Malignancies Market Challenges
Table 15. Hematologic Malignancies Market Restraints
Table 16. Global Hematologic Malignancies Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Hematologic Malignancies Market Share by Players (2016-2021)
Table 18. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2020)
Table 19. Ranking of Global Top Hematologic Malignancies Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Hematologic Malignancies Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hematologic Malignancies Product Solution and Service
Table 23. Date of Enter into Hematologic Malignancies Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Hematologic Malignancies Revenue Market Share by Type (2016-2021)
Table 27. Global Hematologic Malignancies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Hematologic Malignancies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Hematologic Malignancies Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Hematologic Malignancies Revenue Market Share by Application (2016-2021)
Table 31. Global Hematologic Malignancies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Hematologic Malignancies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Hematologic Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Hematologic Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Hematologic Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Hematologic Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Hematologic Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Hematologic Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hematologic Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hematologic Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Hematologic Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Hematologic Malignancies Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Hematologic Malignancies Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Hematologic Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Hematologic Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Hematologic Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hematologic Malignancies Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hematologic Malignancies Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hematologic Malignancies Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Hematologic Malignancies Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer, Inc. Company Details
Table 64. Pfizer, Inc. Business Overview
Table 65. Pfizer, Inc. Hematologic Malignancies Product
Table 66. Pfizer, Inc. Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 67. Pfizer, Inc. Recent Development
Table 68. F. Hoffmann-LA Roche ltd Company Details
Table 69. F. Hoffmann-LA Roche ltd Business Overview
Table 70. F. Hoffmann-LA Roche ltd Hematologic Malignancies Product
Table 71. F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 72. F. Hoffmann-LA Roche ltd Recent Development
Table 73. Sanofi-Aventis Company Details
Table 74. Sanofi-Aventis Business Overview
Table 75. Sanofi-Aventis Hematologic Malignancies Product
Table 76. Sanofi-Aventis Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 77. Sanofi-Aventis Recent Development
Table 78. Bristol-Myers Squibb Company Company Details
Table 79. Bristol-Myers Squibb Company Business Overview
Table 80. Bristol-Myers Squibb Company Hematologic Malignancies Product
Table 81. Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 82. Bristol-Myers Squibb Company Recent Development
Table 83. AbbVie, Inc. Company Details
Table 84. AbbVie, Inc. Business Overview
Table 85. AbbVie, Inc. Hematologic Malignancies Product
Table 86. AbbVie, Inc. Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 87. AbbVie, Inc. Recent Development
Table 88. Novartis AG Company Details
Table 89. Novartis AG Business Overview
Table 90. Novartis AG Hematologic Malignancies Product
Table 91. Novartis AG Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 92. Novartis AG Recent Development
Table 93. GlaxoSmithKline PLC Company Details
Table 94. GlaxoSmithKline PLC Business Overview
Table 95. GlaxoSmithKline PLC Hematologic Malignancies Product
Table 96. GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 97. GlaxoSmithKline PLC Recent Development
Table 98. Celgene Corporation Company Details
Table 99. Celgene Corporation Business Overview
Table 100. Celgene Corporation Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 101. Celgene Corporation Recent Development
Table 102. Johnson & Johnson Services, Inc. Company Details
Table 103. Johnson & Johnson Services, Inc. Business Overview
Table 104. Johnson & Johnson Services, Inc. Hematologic Malignancies Product
Table 105. Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 106. Johnson & Johnson Services, Inc. Recent Development
Table 107. Takeda Pharmaceutical Company limited Company Details
Table 108. Takeda Pharmaceutical Company limited Business Overview
Table 109. Takeda Pharmaceutical Company limited Hematologic Malignancies Product
Table 110. Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2016-2021) & (US$ Million)
Table 111. Takeda Pharmaceutical Company limited Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematologic Malignancies Market Share by Type: 2020 VS 2027
Figure 2. Leukemia Features
Figure 3. Lymphoma Features
Figure 4. Multiple Myeloma Features
Figure 5. Others Features
Figure 6. Global Hematologic Malignancies Market Share by Application: 2020 VS 2027
Figure 7. Chemotherapy Case Studies
Figure 8. Radiotherapy Case Studies
Figure 9. Immunotherapy Case Studies
Figure 10. Stem Cell Transplantation Case Studies
Figure 11. Others Case Studies
Figure 12. Hematologic Malignancies Report Years Considered
Figure 13. Global Hematologic Malignancies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Hematologic Malignancies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Hematologic Malignancies Market Share by Regions: 2020 VS 2027
Figure 16. Global Hematologic Malignancies Market Share by Regions (2022-2027)
Figure 17. Global Hematologic Malignancies Market Share by Players in 2020
Figure 18. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Hematologic Malignancies Revenue in 2020
Figure 20. Global Hematologic Malignancies Revenue Market Share by Type (2016-2021)
Figure 21. Global Hematologic Malignancies Revenue Market Share by Type (2022-2027)
Figure 22. North America Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Hematologic Malignancies Market Share by Type (2016-2027)
Figure 24. North America Hematologic Malignancies Market Share by Application (2016-2027)
Figure 25. North America Hematologic Malignancies Market Share by Country (2016-2027)
Figure 26. United States Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Hematologic Malignancies Market Share by Type (2016-2027)
Figure 30. Europe Hematologic Malignancies Market Share by Application (2016-2027)
Figure 31. Europe Hematologic Malignancies Market Share by Country (2016-2027)
Figure 32. Germany Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Hematologic Malignancies Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Hematologic Malignancies Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Hematologic Malignancies Market Share by Region (2016-2027)
Figure 42. China Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Hematologic Malignancies Market Share by Type (2016-2027)
Figure 50. Latin America Hematologic Malignancies Market Share by Application (2016-2027)
Figure 51. Latin America Hematologic Malignancies Market Share by Country (2016-2027)
Figure 52. Mexico Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Hematologic Malignancies Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Hematologic Malignancies Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Hematologic Malignancies Market Share by Country (2016-2027)
Figure 58. Turkey Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Hematologic Malignancies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Pfizer, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 62. F. Hoffmann-LA Roche ltd Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 63. Sanofi-Aventis Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 64. Bristol-Myers Squibb Company Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 65. AbbVie, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 66. Novartis AG Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 67. GlaxoSmithKline PLC Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 68. Celgene Corporation Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 69. Johnson & Johnson Services, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 70. Takeda Pharmaceutical Company limited Revenue Growth Rate in Hematologic Malignancies Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---